RARE - Ultragenyx Pharmaceutical Short-Term Debt to Capital

Ultragenyx Pharmaceutical (RARE) is pioneering the treatment of orphan diseases by investing massive resources into bioengineering and gene modification. This chart of current share prices with the 0.00 metric is presented alongside data on cryogenic transportation costs for life-saving medications. By holding unique patents in the field of metabolic disorders, Ultragenyx Pharmaceutical (RARE) maintains a monopoly position, fully insulating itself from price competition.

Fundamental asset selection requires an analysis of the liability structure to assess business resilience to changes in borrowing costs. This indicator measures the share of current liabilities in equity, which for Ultragenyx (RARE), possessing pricing power in the orphan drug sector, determines the ability to service debt through premium revenue, as reflected by the history of the short-term debt-to-equity ratio.